Health Economics›Non-small cell lung cancer›Advanced or metastatic disease EGFR inhibitor-naive

Advanced or metastatic disease EGFR inhibitor-naive

Non-small cell lung cancer · 28 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 23 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Carboplatin, Pemetrexed, Amivantamab Variant #01	EGFR	R 753 501	21d	8.9 mo	—	5	R 1 151 463 PFS proxy	2
Lazertinib and Amivantamab Variant #01 Partial	EGFR	R 649 616	28d	23.7 mo	—	2	R 779 539 PFS proxy	2
Osimertinib monotherapy Variant #01	EGFR	R 155 554	28d	16.6 mo	38.1 mo	2	R 311 108 PFS proxy	13
Carboplatin, Osimertinib, Pemetrexed Variant #02	EGFR	R 72 895	21d	8.4 mo	47.5 mo	3	R 218 686 PFS proxy	3
Cisplatin, Osimertinib, Pemetrexed Variant #02	EGFR	R 71 999	21d	8.4 mo	47.5 mo	3	R 215 997 PFS proxy	3
Erlotinib and Ramucirumab Variant #01	EGFR	R 67 170	14d	19.4 mo	—	2	R 134 339 PFS proxy	1
Afatinib monotherapy Variant #01	EGFR	R 26 046	28d	11.0 mo	—	2	R 52 091 PFS proxy	4
Erlotinib and Bevacizumab Variant #01	EGFR	R 26 036	28d	16.7 mo	49.1 mo	52	R 1 353 852 PFS proxy	6
GCP Variant #01	EGFR	R 20 979	21d	16.0 mo	50.9 mo	6	R 125 876 PFS proxy	3
Gefitinib and Pemetrexed Variant #01	EGFR	R 19 642	21d	15.8 mo	—	2	R 39 283 PFS proxy	—
Carboplatin and Pemetrexed Variant #01	EGFR	R 14 563	21d	5.6 mo	22.5 mo	10	R 137 601 PFS proxy	18
Erlotinib monotherapy Variant #01	EGFR	R 13 907	28d	10.2 mo	39.0 mo	2	R 27 814 PFS proxy	17
Cisplatin and Pemetrexed Variant #01	EGFR	R 13 666	21d	5.5 mo	22.5 mo	7	R 95 222 PFS proxy	20
Carboplatin and Gemcitabine/Erlotinib Variant #01	EGFR	R 13 308	28d	7.6 mo	18.3 mo	6	R 79 845 PFS proxy	2
Cisplatin and Gemcitabine/Erlotinib Variant #01	EGFR	R 12 411	28d	7.6 mo	18.3 mo	6	R 74 466 PFS proxy	2
Apatinib and Gefitinib Variant #01 Partial	EGFR	R 8 556	28d	13.7 mo	—	2	R 17 111 PFS proxy	1
Carboplatin and Docetaxel (DCb) Variant #06	EGFR	R 5 501	21d	5.2 mo	—	6	R 33 004 PFS proxy	1
Carboplatin and Gemcitabine (GCb) Variant #01	EGFR	R 4 414	21d	5.2 mo	15.2 mo	2	R 8 829 PFS proxy	4
Gefitinib monotherapy Variant #01	EGFR	R 4 278	28d	10.2 mo	31.8 mo	2	R 8 556 PFS proxy	19
Anlotinib and Gefitinib Variant #01 Partial	EGFR	R 4 278	21d	14.8 mo	—	2	R 8 556 PFS proxy	1
Cisplatin and Gemcitabine (GC) Variant #01	EGFR	R 3 933	21d	5.6 mo	15.2 mo	6	R 23 595 PFS proxy	3
Cisplatin and Docetaxel (DC) Variant #05	EGFR	R 3 185	21d	5.8 mo	—	3	R 9 556 PFS proxy	2
Carboplatin and Paclitaxel (CP) Variant #02	EGFR	R 1 025	21d	5.4 mo	—	12	R 12 296 PFS proxy	1
Icotinib monotherapy Variant #01 Partial	EGFR	—	28d	12.5 mo	—	26	—	2
Dacomitinib monotherapy Variant #01 Partial	EGFR	—	28d	2.9 mo	34.1 mo	2	—	4
Aumolertinib monotherapy Variant #01 Partial	EGFR	—	28d	19.3 mo	—	2	—	1
Lazertinib monotherapy Variant #01 Partial	EGFR	—	28d	20.6 mo	—	2	—	1
Furmonertinib monotherapy Variant #01 Partial	EGFR	—	28d	20.8 mo	—	2	—	1

28 of 28 regimens shown